**Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: a network meta-analysis**

*Running title: NMA of BW in smokers*

Meng-Tsang Hsieh a,1, Ping-Tao Tseng b,1, Yi-Cheng Wu c, Yu-Kang Tu d, Hung-Chi Wu e, Chih-Wei Hsu f, Wei-Te Lei g, Brendon Stubbs h,i,, Andre F. Carvalho j,k, Chih-Sung Liang l,m, Ta-Chuan Yeh n, Tien-Yu Chen o,n, Che-Sheng Chu p,q, Juo-Chi Li p, Chia-Ling Yu r, Yen-Wen Chen s, Dian-Jeng Li e,\*

a Department of Neurology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan

b WinShine Clinics in Specialty of Psychiatry, Kaohsiung City, Taiwan

c Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

d Institute of Epidemiology & Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan

e Department of Addiction Science, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City, Taiwan

f Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

g Division of Allergy, Immunology, Rheumatology Disease, Department of Pediatrics, Mackay Memorial Hospital, Hsinchu, Taiwan

h Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK

i Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, De Crespigny Park, London, UK

j Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

k Centre for Addiction & Mental Health (CAMH), Toronto, ON, Canada

l Department of Psychiatry, Beitou Branch, Tri-Service General Hospital; School of Medicine, National Defense Medical Center, Taipei, Taiwan

m Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan

n Department of Psychiatry, Tri-Service General Hospital; School of Medicine, National Defense Medical Center, Taipei, Taiwan

o Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan

p Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan

q Center for Geriatric and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

r Department of Pharmacy, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan

s Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung, Taiwan

1 : contributed equally as first authors

\*: contributed as corresponding author

**Correspondence to:**

Dian-Jeng Li, MD

Department of Addiction Science, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City, Taiwan

Address: No. 130, Kaisyuan 2nd Rd., Lingya Dist., Kaohsiung City 802, Taiwan

Telephone: +886-7-751-3171 ext. 2343

Fax: +886-7-16-1843

E-mail: edcrfvm45@gmail.com

**Key Points:**

**Question**: Which pharmacologic smoking cessation interventions are associated with the least body weight gain in patients with nicotine dependence?

**Findings:** In this network meta-analysis of 31 randomized control trials with 5650 participants, of all pharmacologic treatments, patients with nicotine patches *plus* fluoxetine/bupropion/topiramate/naltrexone/methylphenidate were associated with less body weight gain than controls. In addition, the nicotine patch *plus* topiramate was associated with the best success rate; the nicotine inhaler was associated with the least drop-out rate. Overall, the nicotine patch 14 mg *plus* fluoxetine 40mg, nicotine patch 14 mg *plus* fluoxetine 40mg, and topiramate 200mg would be the best three pharmacologic treatments based upon both weight gain effect and success rate.

**Meaning**: Nicotine patches *plus* fluoxetine seemed to be associated with the least body weight gain during smoking abstinence.

**Abstract**

Smoking cessation is a public health priority to reduce smoking-related morbidity and mortality. However, weight gain is a known primary reason for not trying to quit smoking.The aim of the current study was to investigate differences in weight gain associated with different pharmacological smoking cessation interventions. Randomized controlled trials (RCTs) which reported weight gain related to pharmacologic treatments for smoking -cessation were analyzed using network meta-analysis with a random effects model. Thirty-one RCTs with 5650 participants were included. Ten drugs and 22 regimens were identified. Nicotine patches *plus* fluoxetine, topiramate with/without nicotine patches, nicotine patches *plus* methylphenidate, nicotine spray/gum/lozenges, high-dose nicotine patches (42 mg/21 mg), naltrexone with/without nicotine patches, or bupropion with/without nicotine patches were associated with less weight gain than the placebo/control arm. Nicotine patches *plus* fluoxetine were associated with the least weight gain of all smoking cessation treatments. In addition, the nicotine patch *plus* topiramate and nicotine inhaler was associated with the best success rate and the least drop-out rate, respectively. Overall, the nicotine patch 14 mg *plus* fluoxetine 40mg, nicotine patch 14 mg *plus* fluoxetine 40mg, and topiramate 200mg would be the best three pharmacologic treatments based upon both weight gain effect and success rate.

*Keywords: nicotine dependence; smoke cessation; adverse effect; body weight; network meta-analysis; weight gain*

**Abbreviations:**

AUC: area under the curve; BW: body weight; CI: confidence interval; DSM: Diagnostic and Statistical Manual of Mental Disorders; ES: effect size; FDA: Food and Drug Administration; ICD: International Classification of Diseases; MD: mean difference; NMA: network meta-analysis; NRT: nicotine replacement therapy; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses; RCT: randomized control trial; SUCRA: surface under the cumulative ranking curve

**Introduction**

Cigarette smoking increases the burden of cardiovascular disease and is associated with 480,000 deaths every year in the United States (1). It is a preventable risk factor for ischemic arterial diseases, and evidence has shown that smoking cessation can decrease the risk of cardiovascular disease and also decrease the associated medical costs (2). Nicotine antagonist and nicotine replacement therapies (NRTs) are widely used for smoking cessation.

Varenicline, bupropion, and NRT alone or in combination have been shown to improve smoking cessation, and also to reduce the cessation failure rate (3). A network meta-analysis (NMA) in 2014 enrolled 21 randomized control trials (RCTs) on NRTs, 28 on bupropion, and 18 on varenicline (3), and found that bupropion and varenicline were not associated with serious cardiovascular diseases, but that NRT was associated with an increase in minor cardiovascular diseases (RR, 2.29; 95% CI, 1.39-3.82). This inconsistency may be because smoking cessation itself can decrease the risk of cardiovascular disease, but weight gain, which is common when using NRT to stop smoking, during and after smoking cessation may contribute to the risk of minor cardiovascular diseases.

Nicotine enhances sympathetic tone and increases metabolism, and stopping smoking and the lack of nicotine can decrease metabolism and promote weight gain (4). Subjects who quit smoking have been reported to have an up to 80% increased likelihood of weight gain (5), and a 1-25% increased likelihood of obesity (6). In a prospective analysis of three cohort studies in the United States (7), smoking quitters had a higher risk of diabetes mellitus (22%) than current smokers, and this risk peaked at 2-7 years after quitting. In addition, most of the quitters with diabetes mellitus had temporary weight gain after smoking cessation, and the mortality rate of the quitters was similar to that of the current smokers during the same period. In another meta-analysis including 35 cohorts (8), the subjects who stopped smoking gained 4.10 kg (95% CI: 2.69-3.60) on average. Concerns about weight gain after stopping smoking are a commonly cited barrier to stopping smoking. For example, an observational study found that women were less likely to quit smoking than men due to concerns about weight gain (9).

Although smoking cessation is a well-known protective factor against cardiovascular diseases, whether or not weight gain after smoking cessation affects the risk of cardiovascular disease is unclear. In most cases, people who quit smoking experience temporary weight gain and have a higher risk of metabolic syndrome (10). The interaction of smoking cessation and metabolic syndrome in quitters is complex and controversial. In a Korean cohort study, post-cessation weight gain did not modify the benefits on coronary heart disease and cardiovascular diseases related to smoking cessation (11). In addition, compared to those who continued to smoke, those who quit had lower rates of myocardial infarction and stroke. Moreover, for those who quit and gained weight, the reduction in the risk of myocardial infarction was greater than for those who did not gain weight (decrease of 67% for myocardial infarction and 25% for stroke in those who gained weight versus 45% and 25%, respectively, in those who did not gain weight).

Achieving sustained smoke cessation is difficult. Malaise, loss of interest, and poor concentration are common symptoms during cessation (12). Concern over post-cessation weight gain is another issue when quitting smoking. Post-cessation weight gain has been linked to difficulty in cessation, delaying the date of cessation, and smoking frequency (13). It is very important to understand the likelihood of weight change when choosing therapy for smoking cessation. Many RCTs and meta-analyses have reported the benefits of smoking cessation with regards to cardiovascular diseases. However, few head-to-head studies have compared the weight gain effect according to smoke cessation medications. Therefore, the aim of the current NMA was to investigate the potential for weight gain with individual pharmacotherapies, including NRTs, bupropion, varenicline, and other Food and Drug Administration (FDA)-approved agents for smoking cessation. Also, in order to provide more clear direction for clinicians to choose pharmacologic interventions, we aimed to integrate the evidence of weight gain and the evidence of success rate of smoking abstinence after pharmacologic interventions for nicotine dependence patients.

**Methods**

*General guidelines applied in the current study*

The current NMA followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) extension guidelines (14) (eTable 1). The current study was also registered at PROSPERO (ID: CRD42018112803).

*Search strategy and selection criteria*

We conducted a systematic review of PubMed, ScienceDirect, ClinicalKey, Cochrane Library, ProQuest, Web of Science, Embase, and ClinicalTrials.gov from inception to October 06, 2018 using the following keywords: “(weight gain OR body weight) AND (tobacco OR smoke prevention OR quit smoke OR smoking abstinence OR smoking cessation OR smoke OR nicotine dependence) AND (nicotine replacement therapy OR NRT OR transdermal nicotine patch OR nikodem OR habitual OR nicotine nasal spray OR nicotra OR nicotine gum OR nicorette OR nicotine lozenge OR commit OR nicorette mini lozenge OR sublingual nicotine tablet OR nicoli OR nicorette OR nicotine inhaler OR nicotra OR nicotine partial agonist OR varenicline OR chantix OR cytisine OR tabes OR nicotine antagonist OR bupropion OR zyban OR mecamylamine OR inversion OR nortriptyline OR pamelor OR clonidine OR nicotine vaccine OR nicvax OR nicotine transdermal drug delivery OR nicotine TTS OR Nicotinell)”. No language restrictions were applied. We also conducted manual searches for potentially eligible articles from the reference lists of review articles and pair-wise meta-analyses (15, 16).

*Inclusion criteria and exclusion criteria*

We only included pharmacologic RCTs, either placebo-controlled or active-controlled, in humans in published articles. Because of the potential heterogeneous sources of the included studies (i.e. from psychiatry, surgery, or medicine specialties), we did not set limitations of standard operationalized diagnostic criteria (*i.e.* Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) codes) to diagnose nicotine dependence.

The exclusion criteria included: (1) not comparing changes in body weight (BW) before and after pharmacologic treatment, (2) lack of adequate controls, (3) also including antipsychotic management, which would have important impact on BW, (4) comorbid with a diagnosis of other substance dependence, (5) not RCTs, (6) not related to smoking abstinence treatment, or (7) including patients with uncontrolled hypertension, pregnancy, depression, psychiatric disorders, seizures or epilepsy, or alcoholism. In cases of duplicated data (*i.e.* different articles based upon the same sample source), we only included the report with the most informative and largest sample source.

*Data extraction*

Two authors (MT Hsieh and PT Tseng) independently screened the studies, extracted the relevant data from the manuscripts, and assessed the risk of bias among the included studies. In cases of discrepancy, a third author (DJ Li) was consulted. If a manuscript lacked eligible data, we contacted the corresponding authors or co-authors to obtain the original data. We followed the flowchart reported in a previous NMA (17-20). With regards to the dosage of investigated medications, we calculated the average dosage during the whole titration course.

*Outcomes*

The primary outcomes were changes in BW before and after pharmacologic treatment for smoking abstinence. The secondary outcome was the success rate of smoking abstinence and drop-out rate by different pharmacologic treatment for smoking abstinence. The definition of success rate was defined as keeping smoking abstinence at the end of study. The definition of drop-out was defined as leaving trial before the end of study regardless of any reasons.

*Cochrane risk of bias tool*

Two independent authors (MT Hsieh and PT Tseng) evaluated the risk of bias (interrater reliability, 0.85) for each domain described in the Cochrane risk of bias tool (21). The studies were then further classified into an overall risk of bias category.

*Statistical analysis*

This NMA was performed using STATA version 14.0. For continuous data, we estimated summary mean differences (MDs) with 95% confidence intervals (CIs) (in units of kg). For dichotomous data, we estimated summary odds ratio (OR) with 95% CIs. Because of the presumed heterogeneity among the included studies, either with regards to the sample source or study methods, we used a random-effects model in pair-wise meta-analysis and frequentist models in the NMA to compare the effect sizes (ESs) between studies with the same interventions. All comparisons were two-tailed, and a *p-*value of 0.05 was considered to be statistically significant. Heterogeneity among the included studies was evaluated using the tau value, which was the estimated standard deviation of the treatment effect across the included studies.

With regards to the meta-analysis procedure applied in this study, we used a mixed treatment comparison with generalized linear mixed models to analyze the direct and indirect comparisons in the NMA (22). Specifically, the indirect comparisons were calculated by transitivity, which indicated that differences between treatment A and B could be calculated from comparisons with third treatment, C. To compare multiple treatment arms, we combined the direct and indirect evidence from the included studies (23). The direct evidence between two treatment arms (*i.e.* treatment A and treatment B) indicated that there had been a direct comparison between treatment A and treatment B in at least one of the included studies. The indirect evidence between two treatment arms (*i.e.* treatment A and treatment C) indicated that we obtained the ESs between treatment A and C through combining the ESs between treatment A and B and the ESs between treatment B and C if we did not have a direct comparison between treatment A and C in the included studies. For example, in eFigure 2A, there was no direct comparison between the nicotine inhaler group and nicotine spray group in the including studies. We therefore obtained indirect evidence between the nicotine inhaler group and nicotine spray group via comparisons with the placebo/control group. In addition, in the figures of network structure, the lines between nodes represented direct comparisons in various trials, and the size of each circle was proportional to the size of the population involved in each specific treatment. The thickness of the lines was proportional to the number of trials connected to the network. We used the mvmeta STATA command in our NMA and self-programmed STATA (24). We also used the restricted maximum likelihood and DerSimonian-Laird methods to evaluate between-study variance (25).

To provide a more relevant clinical application, we calculated the relative ranking probabilities between the treatment effects of all treatments for the target outcomes. In brief, the surface under the cumulative ranking curve (SUCRA) was defined as the percentage of the mean rank of each medication relative to an imaginary intervention that was the best without uncertainty (26). When the area under the curve (AUC) was larger, the treatment had a higher rank with regards to the weight gain effect.

We conducted meta-regression to assess the relationships between the effect on weight gain with individual treatments and the characteristics of the participants, including age, gender distribution, and baseline body-mass index (BMI). To evaluate the effect of potential factors, we selected studies to perform subgroup analysis

Finally, we evaluated potential inconsistencies between the direct and indirect evidence within the network using the loop-specific approach and local inconsistency using the node-splitting method. Furthermore, we used a design-by-treatment model to evaluate the global inconsistency among the whole NMA (27).

**Results**

After the initial screening procedure, 124 articles were considered for full-text review (eFigure 1). Of these studies, 93 were excluded for various reasons (see eFigure 1 and eTable 2 for a summary). Finally, 31 articles were included in the current study (eTable 3). The whole geometric distribution of the treatment arms is provided in eFigure 2A-C.

**Characteristics of the included studies**

Across the 31 RCTs investigating the effect of pharmacologic treatment on weight changes in patients with nicotine dependence, a total of 5650 participants providing data of body weight (mean age of 43.85 years, mean female proportion of 49.38%, and mean BMI=27.6 kg/m2) were included at baseline. The participants smoked between 10-30 cigarettes per day for on average 0.5-3 years. The detailed information of baseline BMI and body weight in each RCTs had been addressed in eTable 3. Among those RCTs, 15 RCTs did not provided baseline body weight and 19 did not provide baseline BMI. Nicotine dependence was determined according to the Fagerström Test for Nicotine Dependence in most of the studies. Among the 31 RCTs, the duration of NRT (16 RCTs) was 2-13 weeks (including 1-6 weeks tapering), including 12-26 weeks for bupropion (4 RCTs), 4-27 weeks for naltrexone (5 RCTs), 13 weeks for phenylpropanolamine gum (1 RCT), 3 weeks for fluoxetine (1 RCT), 12 weeks for lorcaserin (1 RCT), 11 weeks for methylphenidate (1RCT), 10 weeks for topiramate (1 RCT), and 12 weeks for varenicline (1 RCT).

**Primary outcome: Changes in BW before and after pharmacologic treatment for the patients with nicotine dependence**

*Overall geometric structure of the whole network*

All 31 included articles reported changes in BW with different pharmacologic treatments, including 23 treatment arms as follows: topiramate 200 mg, nicotine patch 21 mg *plus* topiramate 200 mg, nicotine patch 14 mg *plus* fluoxetine 40 mg, nicotine patch 42 mg, nicotine patch 14 mg *plus* fluoxetine 20 mg, nicotine patch 21 mg *plus* methylphenidate, nicotine patch 21 mg *plus* naltrexone 25 mg, nicotine patch 21 mg *plus* naltrexone 50 mg, nicotine spray, nicotine patch 21 mg *plus* bupropion 300 mg, phenylpropanolamine gum, bupropion 300 mg, nicotine patch 21 mg *plus* naltrexone 100 mg, nicotine inhaler, nicotine lozenge, naltrexone 50 mg, nicotine patch 14 mg, nicotine patch 21 mg, varenicline 2 mg, nicotine gum, lorcaserin 20 mg, lorcaserin 10 mg, and placebo/control (eFigure 2A and Table 1A).

*Pair-wise meta-analysis*

In the pair-wise meta-analysis, topiramate 200 mg, nicotine spray, nicotine patch 42 mg, nicotine patch 21 mg *plus* topiramate 200 mg, nicotine patch 21 mg *plus* bupropion 300 mg, bupropion 300 mg, nicotine gum, and nicotine patch 14 mg treatment were associated with less weight gain than treatment with a placebo/control [MD = -3.13 (95% CI: -4.39 to -1.86); MD = -2.80 (95% CI: -5.03 to -0.57); MD = -2.50 (95% CI: -3.45 to -1.55); MD = -2.09 (95% CI: -3.23 to -0.95); MD = -0.97 (95% CI: -1.40 to -0.54); MD = -1.25 (95% CI: -2.23 to -0.27); MD = -0.61 (95% CI: -1.13 to -0.10); MD = -0.47 (95% CI: -0.76 to -0.18), respectively].

*NMA*

In the NMA, nicotine patch 14 mg *plus* fluoxetine 40 mg, nicotine patch 14 mg *plus* fluoxetine 20 mg, topiramate 200 mg, nicotine patch 21 mg *plus* methylphenidate, nicotine spray, nicotine patch 42 mg, nicotine patch 21 mg *plus* topiramate 200 mg, nicotine patch 21 mg *plus* naltrexone 25 mg, nicotine patch 21 mg *plus* naltrexone 50 mg, nicotine patch 21 mg *plus* bupropion 300 mg, nicotine lozenge, nicotine patch 21 mg *plus* naltrexone 100 mg, bupropion 300 mg, naltrexone 50 mg, nicotine gum, and nicotine patch 21 mg treatment were associated with less weight gain than treatment with a placebo/control [MD = -4.87 (95% CI: -7.70 to -2.04); MD = -4.28 (95% CI: -7.02 to -1.54); MD = -3.13 (95% CI: -4.60 to -1.65); MD = -2.96 (95% CI: -4.29 to -1.63); MD = -2.80 (95% CI: -5.16 to -0.44); MD = -2.50 (95% CI: -3.72 to -1.28); MD = -2.09 (95% CI: -3.46 to -0.72); MD = -1.90 (95% CI: -2.74 to -1.06); MD = -1.69 (95% CI: -2.44 to -0.94); MD = -1.23 (95% CI: -2.00 to -0.46); MD = -1.20 (95% CI: -2.39 to -0.02); MD = -1.12 (95% CI: -1.96 to -0.28); MD = -1.04 (95% CI: -1.64 to -0.43); MD = -0.85 (95% CI: -1.70 to -0.01); MD = -0.59 (95% CI: -1.17 to -0.01); MD = -0.56 (95% CI: -1.12 to 0.00), respectively] (Table 1A and Figure 1A).

*SUCRA*

We then ranked the changes in BW related to pharmacologic treatment in the patients with nicotine dependence according to SUCRA. In brief, nicotine patch 14 mg *plus* fluoxetine 40 mg treatment was associated with the least weight gain, followed by nicotine patch 14 mg *plus* fluoxetine 20 mg. If we focused on monotherapy, topiramate 200 mg treatment alone was associated with the least weight gain. Finally, if we focused on nicotine products only, nicotine spray was associated with the least weight gain (eTable 4A). Meta-regression using restricted maximum likelihood estimators was performed to examine the potential effect of age, gender distribution (in the form of female proportion), and mean baseline BMI on BW changes. The results of this meta-regression did not reveal a significant effect on BW changes when using age, gender distribution, or mean baseline BMI as a moderating variable.

**Secondary outcome: success rate of smoking abstinence after pharmacologic treatment for the patients with nicotine dependence**

*Overall geometric structure of the whole network*

All 23 included articles reported success rate of smoking abstinence after different pharmacologic management, including 22 treatment arms as follows: topiramate 200 mg, nicotine patch 21 mg *plus* topiramate 200 mg, nicotine patch 14 mg *plus* fluoxetine 40 mg, nicotine patch 42 mg, nicotine patch 14 mg *plus* fluoxetine 20 mg, nicotine patch 21 mg *plus* naltrexone 25 mg, nicotine patch 21 mg *plus* naltrexone 50 mg, nicotine spray, nicotine patch 21 mg *plus* bupropion 300 mg, phenylpropanolamine gum, bupropion 300 mg, nicotine patch 21 mg *plus* naltrexone 100 mg, nicotine inhaler, nicotine lozenge, naltrexone 50 mg, nicotine patch 14 mg, nicotine patch 21 mg, varenicline 2 mg, nicotine gum, lorcaserin 20 mg, lorcaserin 10 mg, and placebo/control (eFigure 2B and Table 1B).

*NMA*

In the NMA, nicotine patch 21 mg *plus* topiramate 200 mg, nicotine patch 21 mg *plus* bupropion 300 mg, lorcaserin 20 mg, nicotine spray, nicotine patch 21 mg *plus* naltrexone 100 mg, bupropion 300 mg, and nicotine patch 14 mg were associated with more success rate than treatment with a placebo/control [OR = 10.50 (95% CI: 1.04 to 105.75); OR = 3.13 (95% CI: 1.59 to 6.16); OR = 3.01 (95% CI: 1.15 to 7.91); OR = 3.17 (95% CI: 1.18 to 8.50); OR = 2.41 (95% CI: 1.13 to 5.15); OR = 2.09 (95% CI: 1.31 to 3.34); OR = 1.84 (95% CI: 1.11 to 3.05), respectively] (Table 1B and Figure 1B).

*SUCRA*

We then ranked the success rate related to different pharmacologic management in the patients with nicotine dependence according to SUCRA. In brief, nicotine patch 21 mg *plus* topiramate 200 mg treatment was associated with the best success rate, followed by topiramate 200 mg, nicotine patch 21 mg *plus* bupropion 300 mg. If we focused on monotherapy, topiramate 200 mg treatment alone was associated with the best success rate. Finally, if we focused on nicotine products only, nicotine spray was associated with the best success rate (eTable 4B). Meta-regression using restricted maximum likelihood estimators was performed to examine the potential effect of age, gender distribution, and mean baseline BMI on success rate. The results of this meta-regression did not reveal a significant effect on success rate when using age, gender distribution, or mean baseline BMI as a moderating variable.

**Secondary outcome: drop-out rate of smoking abstinence after pharmacologic treatment for the patients with nicotine dependence**

*Overall geometric structure of the whole network*

All 11 included articles reported success rate of smoking abstinence after different pharmacologic management, including 17 treatment arms as follows: bupropion 300 mg, varenicline 2 mg, topiramate 200 mg, nicotine lozenge, nicotine gum, nicotine patch 21 mg, nicotine patch 21 mg *plus* naltrexone 25 mg, nicotine patch 21 mg *plus* naltrexone 50 mg, nicotine patch 21 mg *plus* naltrexone 100 mg, nicotine patch 21 mg *plus* bupropion 300 mg, nicotine patch 14 mg, nicotine patch 21 mg *plus* topiramate 200 mg, phenylpropanolamine gum, lorcaserin 20 mg, lorcaserin 10 mg, and nicotine inhaler, and placebo/control (eFigure 2C and Table 1C).

*NMA*

In the NMA, nicotine inhaler, lorcaserin 20 mg, and bupropion 300 mg were associated with less drop-out rate than treatment with a placebo/control [OR = 0.17 (95% CI: 0.06 to 0.52); OR = 0.41 (95% CI: 0.25 to 0.67); OR = 0.67 (95% CI: 0.46 to 0.97), respectively] (Table 1C and Figure 1C).

*SUCRA*

We then ranked the drop-out rate related to different pharmacologic management in the patients with nicotine dependence according to SUCRA. In brief, nicotine inhaler was associated with the least drop-out rate, followed by nicotine patch 21 mg *plus* topiramate 200 mg, lorcaserin 20 mg (eTable 4C). Meta-regression using restricted maximum likelihood estimators was performed to examine the potential effect of age, gender distribution, and mean baseline BMI on drop-out rate. The results of this meta-regression did not reveal a significant effect on drop-out rate when using age, gender distribution, or mean baseline BMI as a moderating variable.

**Risk of bias and publication bias**

We found that 63.6%, 31.8%, and 4.6% of the studies had an overall low, unclear, and high risk of bias, respectively. In addition, an unclear risk of bias due to unclear reporting of randomization procedures or blindness was frequently observed (eFigures 3A-3B, available online).

Funnel plots of publication bias across the included studies (eFigures 4A-4F, available online) revealed general symmetry, and the results of Egger’s test indicated no significant publication bias among the articles included in the NMA. In general, NMAs do not demonstrate inconsistencies in terms of either local inconsistency as assessed using the loop-specific approach and the node-splitting method, or global inconsistency as assessed using the design-by-treatment method (eTable 6-7).

**Discussion**

The main findings of the current NMA are that nicotine patches *plus* other medications, and especially fluoxetine, topiramate alone, bupropion alone, naltrexone alone, nicotine lozenge/gum/spray had superior efficacy in controlling BW with smoking abstinence than placebo treatment. The high-dose nicotine patches (42 mg/21 mg) also had superior efficacy in controlling BW. Among all of the smoking abstinence interventions, nicotine patch 14 mg *plus* fluoxetine 40 mg treatment was associated with the least weight gain. In addition, the nicotine patch 21 mg *plus* topiramate 200 mg was associated with the best success rate, and nicotine inhaler was associated with the least drop-out rate respectively. If we focused on monotherapy, topiramate 200 mg treatment alone was associated with the best success rate and least weight gain. Finally, if we focused on nicotine products only, nicotine spray was associated with the best success rate and least weight gain. The SUCRA ranking of the weight gain and success rate by the investigating pharmacologic treatments had been drawn in the Figure 2. Based upon Figure 2 and calculation of SUCRAweight x SUCRAsuccess, the nicotine patch 14 mg *plus* fluoxetine 40mg, nicotine patch 14 mg *plus* fluoxetine 40mg, and topiramate 200mg would be associated with less weight gain and better success rate among all the pharmacologic treatments.

The most important finding of the current NMA was that the combined treatment group was associated with the least weight gain according to SUCRA. Previous research has suggested that smoking abstinence therapies alone can reduce weight gain after smoking cessation (28, 29), and weight gain has also been reported to be lowest in combined treatment groups (30). It is possible that combined treatment may have a synergistic effect on BW control compared to monotherapy. In the current NMA, SUCRA demonstrated that nicotine patch 14 mg *plus* fluoxetine 40 mg treatment was associated with the least weight gain (reduction of 4.87 kg compared to placebo/control). Fluoxetine, a 5-HT reuptake blocker, has been shown to be an effective anorectic agent during the first few months of treatment (31) (all of the pharmacologic mechanisms are summarized in eTable 5). A previous study also reported that fluoxetine was the least associated with weight gain among all the antidepressants investigated (32). Furthermore, several studies reported that the prescription of fluoxetine in patients with obesity was associated with significant reductions in BW (33, 34). Taken together, nicotine patch 14 mg *plus* fluoxetine 40 mg treatment might be one of the best options for patients with obesity with nicotine dependence.

Another important finding of our NMA was that among the monotherapies for smoking abstinence, topiramate 200 mg treatment alone was associated with the least weight gain. Topiramate, an anticonvulsant prescribed mainly for the treatment of epilepsy and known to induce BW loss (35, 36), has been reported to be capable of diminishing antipsychotic-induced weight gain in schizophrenic patients without aggravating psychotic symptoms (37, 38). In addition, topiramate has also been shown to improve insulin sensitivity, glucose tolerance, and favorably decreased fasting blood glucose, total cholesterol, triglycerides, and high‐density lipoprotein‐cholesterol levels (38-41). Another proposed explanation for the BW loss effect of topiramate is through a reduction in visceral fat associated with a decrease in plasma leptin concentrations and increase in plasma adiponectin concentrations, subsequently leading to an improvement in insulin sensitivity (42). In addition, adverse conditions such as nausea, dyspepsia and diarrhea may also contribute to BW loss. With regards to the biochemical mechanism, it has also been reported that topiramate may inhibit carbonic anhydrase (CAs,EC 4.2.1.1) enzymes involved in several steps of de novo lipogenesis, both in the mitochondria and cytosol of cells, which can result in BW loss (43-45). Another study demonstrated that topiramate can stimulate lipoprotein lipase in adipose tissue and skeletal muscles with a resultant increase in thermogenesis(46, 47). Therefore, topiramate alone may also be suggested for patients with obesity with nicotine dependence.

Topiramate is not only beneficial to weight control but also effective in smoking cessation. We found that topiramate 200 mg treatment alone was associated with the best success rate among monotherapy. As a novel therapy for smoking cessations, topiramate had shown its efficacy in a placebo-controlled RCT (48). It had been reported that topiramate attenuated heart rate increases induced by nicotine and enhance pleasurable feelings, which may be beneficial to smoking cessation (49). One possible mechanism is the enhancement of dopamine release by topiramate in reward system (50). Furthermore, our result demonstrated that nicotine patch 21 mg *plus* topiramate 200 mg was associated with the best success rate. Previous trial also confirmed that combination therapy (nicotine patch plus bupropion) presented the higher long-term rates of smoking cessation than monotherapy (30). The current study indicated the superior efficacy of topiramate not only in monotherapy but also in combination therapy. On the other hand, we reported that nicotine spray was the most effective treatment among NRTs. It was similar to previous meta-analysis, demonstrating that nicotine spray had shown the well-tolerable efficacy for smoking quitting (51).

Finally, in the current NMA, we also found that the NRT alone was also associated with significantly less weight gain than treatment with a placebo/control. Previous studies have reported that higher dosage NRT products such as nicotine gum appear to reduce weight gain during smoking cessation, and thus they have been recommended as a strategy to prevent undesired weight gain (52). Furthermore, high-dose nicotine patch therapy is safe and effective to increase short-term tobacco abstinence and to attenuate both short- and long-term post-cessation weight gain (30).

**Limitations**

Several limitations to the current NMA merit further discussion. First, some of the analyses in this study were limited by underpowered statistics, including heterogeneity in the characteristics of the participants (e.g., underlying diseases, initial severity of nicotine dependence, and trial duration), the small number of trials for some treatment arms, and the heterogeneous route of medication administration. Second, the methodological quality of the included trials may also have contributed to the outcomes, and this may have limited the interpretation. Third, we did not evaluate the cost-benefit of individual pharmacologic interventions in the current study. Finally, because of the heterogeneity of the included study, we could only provide evidences about different of weight gain by individual product compared to the other did but not direct evidence about “how much weight gain did one product result in”.

**Conclusion**

To the best of our knowledge, this is the first systematic review and NMA to investigate the evidence of potential weight gain with individual pharmacotherapies used as part of smoking cessation interventions. Specifically, treatment with topiramate, bupropion, fluoxetine, naltrexone, and NRT *plus* other medications had superior efficacy for BW control than treatment with a placebo. Moreover, combined pharmacotherapy was associated with less weight gain than single medications. In addition, the nicotine patch 21 mg *plus* topiramate 200 mg and nicotine inhaler was associated with the best success rate and the least drop-out rate, respectively. Overall, nicotine patch 14 mg *plus* fluoxetine 40mg, nicotine patch 14 mg *plus* fluoxetine 40mg, and topiramate 200mg would be the best three pharmacologic treatments based upon both weight gain effect and success rate. Further investigations with a longer period of treatment and other medications are warranted to extend our findings.

**Declaration of Interest**

The authors report no financial interests or potential conflicts of interest.

**Acknowledgements**

The authors of this work did not receive any grants of financial support.

The authors contacted Drs. Abelin, T., Adrian H Taylor, Alicia M. Allen, Andrea King, Bess H Marcus, Beth L Nordstrom, Caryn Lerman, Fossati, R., Harry Lando, Henri-Jean Aubin, Hurt, R.D., Jean-Francois Etter, Jessica A. Whiteley, John R Hughes, Jonathan Foulds, Jorenby, D.E., Karen K. Saules, Karen L. Cropsey, Michael C. Fiore, Peter Nilsson, Philip Tonnesen, Phyllis L. Pirie, Robert J. Moffatt, Robyn L. Richmond, Scott J Leischow, Sharon S. Allen, Stephen I. Rennard, Steven G Gourlay, and Stuart Ferguson for further original data, and thank them very much for their help .

Meng-Tsang Hsieh and Ping-Tao Tseng both had full access to all of the data in the study, conducted the data analysis, and took responsibility for the integrity of the data, data analysis, and the accuracy of the data analysis.

Brendon Stubbs holds a Clinical Lectureship supported by Health Education England and the NIHR Integrated Clinical Academic (ICA) Programme (ICA-CL-2017-03-001). Brendon Stubbs is also partly supported by the Maudsley Charity and the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College Hospital NHS Foundation Trust. The views expressed are those of the author[s] and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care

**Figure legends**

**Figure 1. Network structure and forest plot of the current NMA in reference to placebo/control groups.**

Figure 1 indicates the structures of whole network structures of NMA of (A) changes in body weight during smoking abstinence interventions (units: kg), (B) success rate after smoking abstinence interventions, and (C) drop-out rate during smoking abstinence interventions; an ES < 0 indicates (A) less body weight gain and an ES < 1 indicated (B) less success rate or (C) less drop-out rate with an intervention than treatment with a placebo/control during smoking abstinence interventions.

**Figure 2. The scatter plot of different pharmacologic treatments according to SUCRA ranking of weight gain and success rate**

In figure 2, the X axis indicated the SUCRA of weight gain effect; the Y axis indicated the SUCRA of success rate. The less SUCRA, the less weight gain/more success rate was. Therefore, the dot located nearest the zero point would be associated with the least weight gain and best success rate.

Abbreviations: B300mgP21mg: Nicotine patch 21mg + bupropion 300mg; BUP300: Bupropion 300mg; CI: confidence intervals; F20mgP14mg: Nicotine patch 14mg + fluoxetine 20mg; F40mgP14mg: Nicotine patch 14mg + fluoxetine 40mg; GUM: Nicotine gum; INH: Nicotine inhaler; LO10mg: Lorcaserin 10mg; kg: kilogram; LO20mg: Lorcaserin 20mg; LOZ: Nicotine lozenge; MPHP21mg: Nicotine patch 21mg + methylphenidate; N100mgP21mg: Nicotine patch 21mg + naltrexone 100mg; N25mgP21mg: Nicotine patch 21mg + naltrexone 25mg; N50mgP21mg: Nicotine patch 21mg + naltrexone 50mg; NAT50mg: Naltrexone 50mg; P14mg: Nicotine patch 14mg; P21mg: Nicotine patch 21mg; P42mg: Nicotine patch 42mg; PCo: Placebo/control; PPAGUM: Phenylpropanolamine gum; SPR: Nicotine spray; SUCRA: surface under the cumulative ranking curve; T200mgP21mg: Nicotine patch 21mg + topiramate 200mg; TOP200mg: Topiramate 200mg; VAR2mg: Varenicline 2mg

**REFERENCES**

1 Services) HDoHaH. The health consequences of smoking—50 years of progress: A report of the Surgeon General. In: Department of Health and Human Services CfDCaP, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health (ed.). National Center for Chronic Disease Prevention and Health Promotion: Atlanta, GA 2014.

2 Hall W, Doran C. How Much Can the USA Reduce Health Care Costs by Reducing Smoking? *PLoS medicine*. 2016; **13:** e1002021.

3 Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. *Circulation*. 2014; **129:** 28-41.

4 Audrain-McGovern J, Benowitz NL. Cigarette smoking, nicotine, and body weight. *Clin Pharmacol Ther*. 2011; **90:** 164-168.

5 Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. *Bmj*. 2012; **345:** e4439.

6 Flegal KM. The effects of changes in smoking prevalence on obesity prevalence in the United States. *Am J Public Health*. 2007; **97:** 1510-1514.

7 Hu Y, Zong G, Liu G*, et al.* Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. *N Engl J Med*. 2018; **379:** 623-632.

8 Tian J, Venn A, Otahal P, Gall S. The association between quitting smoking and weight gain: a systematic review and meta-analysis of prospective cohort studies. *Obes Rev*. 2015; **16:** 883-901.

9 Walker JF, Loprinzi PD. Association of BMI Changes Between Adolescence and Young Adulthood With Smoking Cessation. *Am J Health Promot*. 2018**:** 890117118772492.

10 Harris KK, Zopey M, Friedman TC. Metabolic effects of smoking cessation. *Nat Rev Endocrinol*. 2016; **12:** 299-308.

11 Kim K, Park SM, Lee K. Weight gain after smoking cessation does not modify its protective effect on myocardial infarction and stroke: evidence from a cohort study of men. *Eur Heart J*. 2018; **39:** 1523-1531.

12 Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev*. 2014**:** CD000031.

13 Germeroth LJ, Levine MD. Postcessation weight gain concern as a barrier to smoking cessation: Assessment considerations and future directions. *Addict Behav*. 2018; **76:** 250-257.

14 Hutton B, Salanti G, Caldwell DM*, et al.* The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med*. 2015; **162:** 777-784.

15 Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *The Cochrane database of systematic reviews*. 2013**:** CD009329.

16 Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. *Obes Rev*. 2004; **5:** 95-103.

17 Cipriani A, Furukawa TA, Salanti G*, et al.* Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. 2018.

18 Lai CC, Tu YK, Wang TG, Huang YT, Chien KL. Effects of resistance training, endurance training and whole-body vibration on lean body mass, muscle strength and physical performance in older people: a systematic review and network meta-analysis. *Age and ageing*. 2018.

19 Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. *PloS one*. 2014; **9:** e99682.

20 Tu YK, Faggion CM, Jr. A primer on network meta-analysis for dental research. *ISRN Dent*. 2012; **2012:** 276520.

21 Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration: 2009.

22 Tu YK. Use of generalized linear mixed models for network meta-analysis. *Med Decis Making*. 2014; **34:** 911-918.

23 Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med*. 2004; **23:** 3105-3124.

24 White IR. Network meta-analysis. *Stata J*. 2015; **15:** 951-985.

25 Kontopantelis E, Springate DA, Reeves D. A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses. *PloS one*. 2013; **8:** e69930.

26 Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol*. 2011; **64:** 163-171.

27 Higgins JP, Del Giovane C, Chaimani A, Caldwell DM, Salanti G. Evaluating the Quality of Evidence from a Network Meta-Analysis. *Value Health*. 2014; **17:** A324.

28 Jorenby DE, Hatsukami DK, Smith SS*, et al.* Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. *Psychopharmacology*. 1996; **128:** 130-138.

29 Leischow SJ, Sachs DP, Bostrom AG, Hansen MD. Effects of differing nicotine-replacement doses on weight gain after smoking cessation. *Arch Fam Med*. 1992; **1:** 233-237.

30 Jorenby DE, Leischow SJ, Nides MA*, et al.* A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med*. 1999; **340:** 685-691.

31 Goldstein DJ, Rampey AH, Jr., Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. *Int J Obes Relat Metab Disord*. 1994; **18:** 129-135.

32 Uguz F, Sahingoz M, Gungor B, Aksoy F, Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. *General hospital psychiatry*. 2015; **37:** 46-48.

33 Levine LR, Rosenblatt S, Bosomworth J. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. *International journal of obesity*. 1987; **11 Suppl 3:** 185-190.

34 Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. *Am J Clin Nutr*. 1991; **54:** 321-325.

35 Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. *Obesity research*. 2003; **11:** 556-562.

36 Lee IH, Cheng CC, Yang YK, Yeh TL, Chen PS, Chiu NT. Correlation between striatal dopamine D2 receptor density and neuroticism in community volunteers. *Psychiatry research*. 2005; **138:** 259-264.

37 Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. *Schizophr Res*. 2006; **82:** 115-117.

38 Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. *Schizophr Res*. 2010; **118:** 218-223.

39 Astrup A, Caterson I, Zelissen P*, et al.* Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. *Obesity research*. 2004; **12:** 1658-1669.

40 Bray GA, Hollander P, Klein S*, et al.* A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. *Obesity research*. 2003; **11:** 722-733.

41 Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, Group O-S. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. *Int J Obes Relat Metab Disord*. 2004; **28:** 1399-1410.

42 Schutt M, Brinkhoff J, Drenckhan M, Lehnert H, Sommer C. Weight reducing and metabolic effects of topiramate in patients with migraine--an observational study. *Exp Clin Endocrinol Diabetes*. 2010; **118:** 449-452.

43 Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. *CNS Drugs*. 2008; **22:** 27-47.

44 Schneiderhan ME, Marvin R. Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain? *American journal of therapeutics*. 2007; **14:** 581-584.

45 Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. *Expert Opin Emerg Drugs*. 2012; **17:** 11-15.

46 Astrup A, Toubro S. Topiramate: a new potential pharmacological treatment for obesity. *Obesity research*. 2004; **12 Suppl:** 167S-173S.

47 Halpern B, Oliveira ES, Faria AM*, et al.* Combinations of drugs in the Treatment of Obesity. *Pharmaceuticals (Basel)*. 2010; **3:** 2398-2415.

48 Oncken C, Arias AJ, Feinn R*, et al.* Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. *Nicotine Tob Res*. 2014; **16:** 288-296.

49 Sofuoglu M, Poling J, Mouratidis M, Kosten T. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. *Psychopharmacology*. 2006; **184:** 645-651.

50 Okada M, Yoshida S, Zhu G, Hirose S, Kaneko S. Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems. *Neuroscience*. 2005; **134:** 233-246.

51 Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. *The Cochrane database of systematic reviews*. 2018; **5:** CD000146.

52 Doherty K, Militello FS, Kinnunen T, Garvey AJ. Nicotine gum dose and weight gain after smoking cessation. *Journal of consulting and clinical psychology*. 1996; **64:** 799-807.